Skip to main content
. 2016 Jun 8;2:16017. doi: 10.1038/npjbcancer.2016.17

Figure 1.

Figure 1

Five-year estimates of breast-cancer-specific mortality, by Recurrence Score group (prespecified primary analysis). Patients with HR+, HER2-negative, node-negative breast cancer who had Recurrence Score (RS) results <18 (green), 18–30 (yellow), or ⩾31 (red) were included in the primary analysis. Five-year estimates of breast-cancer-specific mortality (BCSM) with 95% CIs (green, yellow, and red shading) were 0.4% (0.3–0.6%) in the RS <18 group, 1.4% (1.1–1.7%) in the RS 18–30 group, and 4.4% (3.4–5.6%) in the RS ⩾31 group. Five-year estimates of BCSM±s.e. are shown to the right of their respective lines. Numbers of patients at risk in each group are shown beneath the graph.